Inhibitor ribonukleotidne reduktaze
Inhibitori ribonukleotidne reduktaze su familija antikancerni lekovi koji ometaju rast ćelija tumora blokiranjem formiranja dezoksiribonukleotida (gradivnih blokova DNK).
- Primeri
- Moteksafin gadolinijum.[1]
- hidroksiureja[2]
- Fludarabin, kladribin, gemcitabin, tezacitabin, i triapin[3]
- Galijum maltolat, galijum nitrat[4]
Reference[uredi | uredi izvor]
- ^ Zahedi Avval F, Berndt C, Pramanik A, Holmgren A (januar 2009). „Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)”. Biochem. Biophys. Res. Commun. 379 (3): 775—9. PMID 19121624. doi:10.1016/j.bbrc.2008.12.128.
- ^ Mayhew CN, Phillips JD, Cibull ML, Elford HL, Gallicchio VS (septembar 2002). „Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea”. Antivir. Chem. Chemother. 13 (5): 305—14. PMID 12630679.
- ^ Tsimberidou AM, Alvarado Y, Giles FJ (avgust 2002). „Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies”. Expert Rev Anticancer Ther. 2 (4): 437—48. PMID 12647987. doi:10.1586/14737140.2.4.437.
- ^ Bernstein, LR (1998). „Mechanisms of therapeutic activity for gallium” (PDF). Pharmacol. Rev. 50 (4): 665—682. PMID 9860806. Arhivirano iz originala (PDF) 26. 02. 2007. g. Pristupljeno 12. 07. 2014.